CAMP4 THERAPEUTICS CORPORATION
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| CAMP | FDMT | PRQR | RNA | XFOR | TRDA | |
|---|---|---|---|---|---|---|
| Market cap | 234.70M | 678.40M | 198.98M | 148.48M | 321.24M | 197.02M |
| P/E (TTM) | — | — | — | — | 162.0 | — |
| Forward P/E | -4.4 | -3.0 | -3.0 | -1.5 | -4.2 | -1.6 |
| Price/book | -287.7 | 1.7 | 2.2 | 0.7 | 1.6 | 0.8 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −15.96% | +12.45% | −36.20% | −41.15% | −7.56% | −27.19% |
| Today | −2.35% | +2.76% | +2.92% | −0.46% | +2.21% | +7.20% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All CAMP news ›CAMP4 Therapeutics (NASDAQ:CAMP) Stock Picked Up by Analysts at Raymond James Financial
Posted by Danessa Lincoln on Oct 23rd, 2026 Get Our Latest Stock Analysis on CAMP CAMP stock opened at $3.39 on Friday. The business’s 50-day moving average is $4.04 and its two-hundred day moving average is $4.14. CAMP4 Therapeutics has a…
CAMP4 Therapeutics Receives Authorization in the United Kingdom for Phase 1/2 Human Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder
CAMP4 Therapeutics Receives Authorization in the United Kingdom for Phase 1/2 Human Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disor
Camp4 Therapeutics Corp Registered Shs Stock , CAMP
The latest Camp4 Therapeutics stock prices, stock quotes, news, and CAMP history to help you invest and trade smarter. Camp4 Therapeutics Corp Registered Shs Stock , CAMP Camp4 Therapeutics Stock Snapshot Camp4 Therapeutics News More News…
CAMP4 Therapeutics to Host Virtual Analyst Day to Discuss CMP-002 for the Treatment of SYNGAP1-Related Disorder on September 28, 2026
WATERTOWN, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory ... CAMP4 Therapeutics to Host Virtual Analyst Day…
Camp4 Therapeutics price target lowered to $6 from $6.50 at Chardan
Chardan analyst Keay Nakae lowered the firm’s price target on Camp4 Therapeutics (CAMP) to $6 from $6.50 and keeps a Buy rating on the shares fo... Camp4 Therapeutics price target lowered to $6 from $6.50 at Chardan Chardan analyst Keay…
Piper Sandler Sticks to Its Buy Rating for CAMP4 Therapeutics Corporation (CAMP)
In a report released today, Edward Tenthoff from Piper Sandler reiterated a Buy rating on CAMP4 Therapeutics Corporation, with a price target of $15.00. Tenthoff covers the Healthcare sector, focusing on stocks such as Arrowhead…
Camp4 Therapeutics initiated with an Outperform at Oppenheimer
Oppenheimer initiated coverage of Camp4 Therapeutics (CAMP) with an Outperform rating and $15 price target. The firm believes Camp4’s $190M EV d... Camp4 Therapeutics initiated with an Outperform at Oppenheimer Oppenheimer initiated…
CAMP4 to Participate in Upcoming Investor Conferences
WATERTOWN, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage ... CAMP4 to Participate in Upcoming Investor Conferences WATERTOWN, Mass., Sept. 01, 2026…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- markets.businessinsider.com7
- themarketsdaily.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 8 articles, not a forecast.